Recognition for outstanding teams in anti-epidemic and flood-fighting

Retrograde Model Award and Togetherness Award

Liu Wei, General Manager of Shenyang Hongqi Pharmaceutical Co., Ltd.

    Through the joint efforts of everyone in the first half of the year, although the economic indicators did not meet expectations, there were notable bright spots in all sectors. In the second half of the year, in the context of economic contraction, we need to face the difficulties and focus on the development of key areas in combination with the current situation of Hongqi and the needs of strategic development. The first is to focus on the improvement of the quality system and meet the WHO PQ certification standards; the second is to focus on the core areas of tuberculosis and urology andrology for BD and R&D to create a technology platform with Hongqi characteristics; at the same time, the internal operation system should emphasize high efficiency, lean operation, and efficient operation, so as to improve the human efficiency, material efficiency, and process efficiency; in the second half of the year, organizational changes will be carried out to complete echelon construction and adapt to business development.

Yang Bo, Chairman of Shenyang Hongqi Pharmaceutical Co., Ltd.

    Thank you for your hard work in the first half of the year. Although we did not achieve our budget target, your work performance is still worthy of recognition. Everyone played to their strengths and also reflected on their own problems and formulated the next steps. Under the changing situation of the pharmaceutical industry, it is both a crisis and an opportunity, and we must seize the opportunity to seek development. The organizational system of marketing has been upgraded recently, forming an organizational structure in which the three business divisions are promoted in parallel. The newly established PHS business unit is the foundation of the company's public health service system and the core competitiveness of Hongqi Pharma in the entire public health system. In the second half of the year, marketing and R&D are the twin engines of the company's development. How to make efforts to achieve performance growth requires the efforts of all Hongqi people.

Mr. Wen Deyong, Fosun Global Partner and CEO of Fosun Pharma

    After several years of development, Shenyang Hongqi Pharmaceutical has overcome many difficulties and difficulties under the leadership of Chairman Yang Bo, and has developed very brightly in the field of tuberculosis. If Hongqi successfully opens the international market through PQ in the future, it will be a good development opportunity for Hongqi, and it will usher in an accelerated growth in sales performance. At the same time, we also need to think about the height of the red flag in the next five years. Now it is a Chinese brand, and it may be in Africa or the Middle East in the future, or whether it can become a global brand. We must have full confidence in the future development of Hongqi. It is hoped that in the future development, every student can find their own role in the actual work, and their career development will get better and better.

meeting venue

Li Feng-Review of H1 business status in 2022	Li Penghua-Marketing system H1 work summary and H2 work plan
Liu Yazhou-R&D and BD H1 work summary and H2 work plan	Ma Minghong-Production system H1 work summary and H2 work plan
Xu Linlin-Summary of H1 work of quality system and H2 work plan	Li Lei-Supply chain H1 work summary and H2 work plan
Liu Huaqing-EHS and Lean H1 work summary and H2 work plan	Lu Wenhua-Human Resources H1 work summary and H2 work plan
Yang Joy-Hainan company H1 work summary and H2 work plan	Gu Qiqiao - H1 Outstanding Commendation